TriangleNCT03409614 · OUTCOME
Part 1: Number of Deaths During the On-Treatment Period
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Up to 28 months
What was measured
The on-treatment period was defined as the day from the first dose of study drug to the day of the last dose of study drug plus 90 days or 1 day before participants receive their first dose of new anti-cancer systemic therapy, whichever is earlier.
Analysis population: Randomized and treated Part 1 participants only
Groups in this outcome
Part 1: Cemiplimab + Chemotherapy
Participants received cemiplimab plus platinum-based doublet chemotherapy
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
Participants received cemiplimab plus platinum-based doublet chemotherapy and ipilimumab
Part 1: Chemotherapy
Participants received platinum-based doublet chemotherapy
| Group | Source count |
|---|---|
| Part 1: Cemiplimab + Chemotherapy | 108 |
| Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | 109 |
| Part 1: Chemotherapy | 103 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: Cemiplimab + Chemotherapy | 36 | Not reported | Not reported | Not reported | Not reported |
| Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | 24 | Not reported | Not reported | Not reported | Not reported |
| Part 1: Chemotherapy | 18 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 36
- group Id
- OG001
- value
- 24
- group Id
- OG002
- value
- 18
- denoms
- counts
- group Id
- OG000
- value
- 108
- group Id
- OG001
- value
- 109
- group Id
- OG002
- value
- 103
- units
- Participants
- description
- The on-treatment period was defined as the day from the first dose of study drug to the day of the last dose of study drug plus 90 days or 1 day before participants receive their first dose of new anti-cancer systemic therapy, whichever is earlier.
- groups
- description
- Participants received cemiplimab plus platinum-based doublet chemotherapy
- id
- OG000
- title
- Part 1: Cemiplimab + Chemotherapy
- description
- Participants received cemiplimab plus platinum-based doublet chemotherapy and ipilimumab
- id
- OG001
- title
- Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
- description
- Participants received platinum-based doublet chemotherapy
- id
- OG002
- title
- Part 1: Chemotherapy
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Randomized and treated Part 1 participants only
- reporting Status
- POSTED
- time Frame
- Up to 28 months
- title
- Part 1: Number of Deaths During the On-Treatment Period
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice